Harbor Investment Advisory LLC Has $3.85 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Harbor Investment Advisory LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,664 shares of the biopharmaceutical company’s stock after selling 100 shares during the quarter. Harbor Investment Advisory LLC’s holdings in Regeneron Pharmaceuticals were worth $3,852,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of REGN. West Paces Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares during the period. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $26,000. Sachetta LLC raised its holdings in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. Crewe Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $28,000. Finally, Lynx Investment Advisory acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Canaccord Genuity Group restated a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Argus lifted their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Finally, Guggenheim raised their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,119.00.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $1.77 on Friday, reaching $1,012.82. The stock had a trading volume of 1,071,799 shares, compared to its average volume of 491,440. The firm has a fifty day moving average of $1,125.65 and a two-hundred day moving average of $1,036.98. The company has a market cap of $111.60 billion, a P/E ratio of 29.92, a price-to-earnings-growth ratio of 3.56 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the previous year, the company earned $8.79 EPS. The business’s revenue was up 12.3% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Insiders Place Their Bets

In other news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 8,033 shares of company stock worth $9,399,345 in the last 90 days. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.